Vascular endothelial growth factor: basic science and clinical progress

N Ferrara - Endocrine reviews, 2004 - academic.oup.com
Vascular endothelial growth factor (VEGF) is an endothelial cell-specific mitogen in vitro and
an angiogenic inducer in a variety of in vivo models. Hypoxia has been shown to be a major …

Vascular endothelial growth factor as an anti-angiogenic target for cancer therapy

G Niu, X Chen - Current drug targets, 2010 - ingentaconnect.com
New blood vessel formation (angiogenesis) is fundamental to tumor growth, invasion, and
metastatic dissemination. The vascular endothelial growth factor (VEGF) signaling pathway …

World Health Organization classification of tumours: Pathology & genetics of tumours of the urinary system and male genital organs

TY Chan - Urology, 2005 - goldjournal.net
This 2004 volume in the World Health Organization series on histologic and genetic typing
of human tumors covers tumors of the kidney, urinary system, prostate, testis and …

Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein

K Kondo, J Klco, E Nakamura, M Lechpammer… - Cancer cell, 2002 - cell.com
Inactivation of the von Hippel-Lindau tumor suppressor gene is linked to the development of
hereditary (VHL Disease-associated) and sporadic clear cell carcinoma of the kidney. The …

[HTML][HTML] Role of vascular endothelial growth factor in the regulation of angiogenesis

N Ferrara - Kidney international, 1999 - Elsevier
Role of vascular endothelial growth factor in the regulation of angiogenesis. Compelling
evidence indicates that vascular endothelial growth factor (VEGF) is a fundamental regulator …

VEGF165b, an Inhibitory Splice Variant of Vascular Endothelial Growth Factor, Is Down-Regulated in Renal Cell Carcinoma

DO Bates, TG Cui, JM Doughty, M Winkler, M Sugiono… - Cancer research, 2002 - AACR
Angiogenesis is essential for tumor growth. Vascular endothelial growth factor (VEGF) is the
most potent growth factor of tumor neovasculature, has been shown to be up-regulated in …

Inhibition of HIF2α is sufficient to suppress pVHL-defective tumor growth

K Kondo, WY Kim, M Lechpammer, WG Kaelin Jr - PLoS biology, 2003 - journals.plos.org
Biallelic inactivation of the von Hippel–Lindau tumor suppressor gene (VHL) is linked to the
development of hereditary (VHL-associated) and sporadic clear-cell renal carcinomas as …

The role of vascular endothelial growth factor in angiogenesis

N Ferrara, HP Gerber - Acta haematologica, 2001 - karger.com
Vascular endothelial growth factor (VEGF) is an endothelial cell-specific mitogen and an
angiogenic inducer as well as a mediator of vascular permeability. The biological effects of …

Biology and clinical development of vascular endothelial growth factor–targeted therapy in renal cell carcinoma

BI Rini, EJ Small - Journal of Clinical Oncology, 2005 - ascopubs.org
Purpose To review the biology of renal cell carcinoma (RCC) leading to vascular endothelial
growth factor (VEGF) overexpression and the clinical results of VEGF blockade in metastatic …

Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic

G Ranieri, R Patruno, E Ruggieri… - Current medicinal …, 2006 - ingentaconnect.com
Angiogenesis is important in the growth and progression of solid tumours. The main pro-
angiogenic factor, namely vascular endothelial growth factor (VEGF), also known as …